RCS - ReNeuron Group plc - ReNeuron wins Breakthrough of the Year Award

ReNeuronAnnouncement

14/06/2019 11:10

RNS Number : 3382C
ReNeuron Group plc
14 June 2019
 


 
 



 
 
 
 
14 June 2019


 
 
 
 
                                                              AIM: RENE




 


 



RNS Reach
 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
ReNeuron wins Breakthrough of the Year Award
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the 'Breakthrough of the Year' award at last night's 2019 European Mediscience Awards in London.
 
This award underlines the strong clinical development and commercial progress ReNeuron has made over the past year.  This includes positive data from the ongoing Phase 1/2a clinical trial in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.
 
Olav Hellebø, Chief Executive Officer of ReNeuron, commented:
 
"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards. We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."
 
The European Mediscience Awards is one of the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.  It celebrates the best in the sector and highlights the achievements of individuals and companies operating within it.
 
ENDS
 



Contacts:
 
ReNeuron


 
 
+44 (0) 20 3819 8400




Olav Hellebø, Chief Executive Officer




Michael Hunt, Chief Financial Officer




 
Buchanan (UK Media/Investor Relations)


 
+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham




 
Argot Partners (US Media/Investor Relations)
Stephanie Marks, Claudia Styslinger


 
+1 212 600 1902




 
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison


 
+44 (0) 20 7710 7600
 




 
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor


 
+44 (0) 20 7496 3000




 


 



About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRACKQDKKBKDOAD